Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CervoMed Inc.CRVO · Entity 7338 | Director | June 08, 2026 | June 10, 2026 |
| PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478 | Director | June 09, 2020 | June 12, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CervoMed Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2036-06-08 | Direct | 8,150 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 8,150 · Balance 8,150 F1: On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
PUMA BIOTECHNOLOGY, INC.
Report date June 09, 2020 · Filed June 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 50,993 |
Reported balance
After 2020-06-09 transaction · row 1
1 source rowRow 1 · 2020-06-09 · Grant · Acquired 25,748 · Balance 50,993 F1: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. |
| COMMON STOCKSEC Table I · non-derivative | IndirectBy Dynasty Trust | 359,076 |
Reported balance
Holding disclosure · report date 2020-06-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 359,076 |
| COMMON STOCKSEC Table I · non-derivative | IndirectBy Spouse Dynasty Trust | 550,000 |
Reported balance
Holding disclosure · report date 2020-06-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 550,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 10, 2026 23:45 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 8,150 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001437749-26-020217 · rdgdoc.xml · derivative · entry 1 ZAVRL FRANK · CIK 0001652169 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,150 Underlying: Common Stock · 8,150 shares Expires 2036-06-08 F1 · derivative.exercise_date: On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:04 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 8,100 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001437749-25-021274 · rdgdoc.xml · derivative · entry 1 ZAVRL FRANK · CIK 0001652169 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,100 Underlying: Common Stock · 8,100 shares Expires 2035-06-23 F1 · derivative.exercise_date: On June 23, 2025, in connection with the Reporting Person's election to the Issuer's board of directors at its 2025 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,100 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 22:19 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 5,750 | $0.00 Strike: $19.01 | $0.00 |
DisclosureSEC source: 0001437749-24-020408 · rdgdoc.xml · derivative · entry 1 ZAVRL FRANK · CIK 0001652169 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750 Underlying: Common Stock · 5,750 shares Expires 2034-06-14 F1 · derivative.exercise_date: On June 14, 2024, in connection with the Reporting Person's election to the Issuer's board of directors at its 2024 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 5,750 shares of the Issuer's common stock under the Issuer's 2015 Equity Incentive Plan, as amended, in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| September 15, 2023 Filed Sep 15, 2023 22:53 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 6,450 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001437749-23-026075 · rdgdoc.xml · derivative · entry 1 ZAVRL FRANK · CIK 0001652169 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,450 Underlying: Common Stock · 6,450 shares Expires 2033-09-15 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing September 30, 2023. Read SEC document |
| June 09, 2020 Filed Jun 12, 2020 00:11 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 25,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036130 · doc4.xml · nonDerivative · entry 1 ZAVRL FRANK · CIK 0001652169 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,993 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 10, 2019 Filed Jun 13, 2019 01:02 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 19,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036581 · doc4.xml · nonDerivative · entry 1 ZAVRL FRANK · CIK 0001652169 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,245 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 23:29 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 5,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-037896 · doc4.xml · nonDerivative · entry 1 ZAVRL FRANK · CIK 0001652169 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,822 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 22:13 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 7,604 | $0.00 Strike: $79.20 | $0.00 |
DisclosureSEC source: 0001209191-17-039915 · doc4.xml · derivative · entry 1 ZAVRL FRANK · CIK 0001652169 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,604 Underlying: Common Stock · 7,604 shares Expires 2027-06-11 F1 · derivative.exercise_date: The option vests in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| November 14, 2016 Filed Nov 16, 2016 22:53 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $40.10 | $0.00 |
DisclosureSEC source: 0001209191-16-150643 · doc4.xml · derivative · entry 1 ZAVRL FRANK · CIK 0001652169 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-11-13 F1 · derivative.exercise_date: The vesting commencement date ("VCD") of the option is November 14, 2016. The option vests (i) with respect to one-third (1/3) of the shares underlying the option on the first anniversary of the VCD and (ii) with respect to 1/36th of the shares underlying the option, on each monthly anniversary of the VCD thereafter, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.